Feb 22, 2023 / 01:00PM GMT
Martin Welschof - BioInvent International AB - CEO
Thank you very much, and welcome, everybody, to our call. And we'll ride jump into the first slide. So CEO, Martin Welschof, the CEO; and Stefan Ericsson, the CFO.
Our forward-looking statement and then the summary. So basically, I just want to go briefly through the events during the fourth quarter.
We started our Phase 1 trial with the subcutaneous formulation of the BI-1206. Then we received notice of allowance in the US for quite important patent covering BI-1206 and BI-1607. And then as I will show you later, we have strong progress in clinical and preclinical projects. So our pipeline is growing basically forward as projected and planned. And that was also covered during our R&D Day that we had in December 2022 in Stockholm.
And then, the other thing that we also we're quite proud about was that BioInvent and Transgene had a joint paper on BT-001, which is our joint collaboration. We won the JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022. And then we also received last but not least, IND FDA approval
Full Year 2022 BioInvent International AB Earnings Call Transcript
Feb 22, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers